Polypid LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ

25 Feb 2026

PYPD

Polypid LTD

20-F: PolyPid's D-PLEX100 Achieves Phase 3 Success, Eyes 2026 NDA

PolyPid Ltd. reported positive topline results from its pivotal SHIELD II Phase 3 trial for D-PLEX100, showing significant reduction in surgical site infections, and plans for a rolling NDA submission by Q1 2026.

NASDAQ

26 Feb 2025

PYPD

Polypid LTD

20-F: PolyPid Secures Loan Amendment Amidst Ongoing Clinical Trials and Financial Reporting

PolyPid amends its loan agreement with Kreos Capital while continuing Phase 3 trials for D-PLEX100 and reporting financial results for 2024.

NASDAQ

6 Mar 2024

PYPD

Polypid LTD

20-F: PolyPid Details Share Structure and Corporate Governance in 20-F Filing

PolyPid's 20-F filing outlines the rights, powers, and limitations of its securities, directors, and shareholders under Israeli law.